Publications by authors named "Xianwei Ha"

Claim this Profile
I
Improved benefit of continuing luspatercept therapy: sub-analysis of patients with lower-risk MDS in the MEDALIST study.
Ulrich Germing, Pierre Fenaux, Uwe Platzbecker, Rena Buckstein, Valeria Santini, Shannon Fabre, George Zhang, Xianwei Ha

Ann Hematol· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Longer-term benefit of luspatercept in transfusion-dependent lower-risk myelodysplastic syndromes with ring sideroblasts.
Amer M Zeidan, Uwe Platzbecker, Guillermo Garcia-Manero, Mikkael A Sekeres, Pierre Fenaux, Michael R Savona, Jennie Zhang, George Zhang, Xianwei Ha

Blood· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Luspatercept for myelodysplastic syndromes/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis.
Rami S Komrokji, Uwe Platzbecker, Pierre Fenaux, Amer M Zeidan, Guillermo Garcia-Manero, Michael R Savona, George Zhang, Xianwei Ha

Leukemia· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health-Related Quality of Life Outcomes in Patients with Myelodysplastic Syndromes with Ring Sideroblasts Treated with Luspatercept in the MEDALIST Phase 3 Trial.
Esther Natalie Oliva, Uwe Platzbecker, Guillermo Garcia-Manero, Ghulam J Mufti, Valeria Santini, George Zhang, Xianwei Ha

J Clin Med· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and tolerability of switching to asenapine from other antipsychotic agents: pooled results from two randomized multicenter trials in stable patients with persistent negative symptoms in schizophrenia.
Pilar Cazorla, Mary Mackle, Jun Zhao, Xianwei Ha, Armin Szegedi

Neuropsychiatr Dis Treat· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Asenapine versus olanzapine in people with persistent negative symptoms of schizophrenia.
Robert W Buchanan, John Panagides, Jun Zhao, Phillip Phiri, Wil den Hollander, Xianwei Ha

J Clin Psychopharmacol· February 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis